Insider · CIK 0001038977
Michael S Weiss
Files at TGTX (TG THERAPEUTICS, INC.), FBIO (Fortress Biotech, Inc.), CKPT (Checkpoint Therapeutics, Inc.). First filing Nov 16, 2023, latest Nov 16, 2023.
In brief
Michael S Weiss files SEC Form 4 as director, chair, CEO and 10% owner at FBIO (Fortress Biotech, Inc.), and also at TGTX (TG THERAPEUTICS, INC.), CKPT (Checkpoint Therapeutics, Inc.). Since Nov 16, 2023, Michael S Weiss has reported 1 open-market buy worth $250k and 0 open-market sells worth $0, the latest filed on Nov 16, 2023.
A track record needs three past buys with six months of prices behind them; Michael S Weiss has 0, so none is measured yet.
The newest scored trade: bought $250k of FBIO on Nov 14, 2023, filed Nov 16, 2023, scored 39 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
FBIO: Fortress Biotech, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Fortress Biotech, Inc. | $250k 147,058 shares | +15% | - |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | FBIO Fortress Biotech, Inc. | AGrant or award common stock, par value $0.001 | +475,424 | $0.00 | $0 | 2,276,562 | Mar 20, 2026 |
| Jan 8, 2026 | TGTX TG THERAPEUTICS, INC. | AGrant or award Common Stock | +622,000 | $0.00 | $0 | 9,778,086 | Jan 9, 2026 |
| Nov 5, 2025 | TGTX TG THERAPEUTICS, INC. | GGift Common Stock | -3,865,126 | $0.00 | $0 | 9,959,803 | Nov 7, 2025 |
| Nov 5, 2025 | TGTX TG THERAPEUTICS, INC. | GGift Common Stock | -803,717 | $0.00 | $0 | 9,156,086 | Nov 7, 2025 |
| May 28, 2025 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCKindirect: See Note 2 | +12,195 | $0.00 | $0 | 137,007 | May 30, 2025 |
| May 29, 2025 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCK | +50,000 | $1.29 | $65k | 187,007 | May 30, 2025 |
| May 30, 2025 | CKPT Checkpoint Therapeutics, Inc. | UTender of shares COMMON STOCKindirect: See Note 2 | -187,007 | - | - | 0 | May 30, 2025 |
| Jan 1, 2025 | FBIO Fortress Biotech, Inc. | AGrant or award common stock, par value $0.001 | +454,153 | $0.00 | $0 | 1,801,138 | Jan 3, 2025 |
| Dec 13, 2024 | CKPT Checkpoint Therapeutics, Inc. | AGrant or award COMMON STOCKindirect: See Note 3 | +12,638 | $0.00 | $0 | 124,812 | Dec 17, 2024 |
| Jan 6, 2024 | TGTX TG THERAPEUTICS, INC. | AGrant or award Common Stock | +1,001,908 | $0.00 | $0 | 13,074,929 | Jan 8, 2024 |
| Jan 1, 2024 | FBIO Fortress Biotech, Inc. | AGrant or award COMMON STOCK, PAR VALUE $0.001 | +216,465 | $0.00 | $0 | 1,346,985 | Jan 3, 2024 |
| Nov 14, 2023 | FBIO Fortress Biotech, Inc. | POpen-market purchase COMMON STOCK, PAR VALUE $0.001 | +147,058 | $1.70 | $250k | 1,130,520 | Nov 16, 2023 |
| Nov 14, 2023 | FBIO Fortress Biotech, Inc. | POpen-market purchase Warrants to purchase Common Stockderivative | +147,058 | $0.00 | $0 | 147,058 | Nov 16, 2023 |
Questions about Michael S Weiss
Answered from the filings on this page, as of the latest one.
Is Michael S Weiss buying or selling?
Not in the last 12 months. Michael S Weiss's latest open-market trade on SEC Form 4 was bought $250k of FBIO on Nov 14, 2023.
How did Michael S Weiss's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael S Weiss has 0.
Where does Michael S Weiss file Form 4?
Michael S Weiss has filed Form 4 at FBIO (Fortress Biotech, Inc.) as See Remarks; TGTX (TG THERAPEUTICS, INC.) as CEO; CKPT (Checkpoint Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.